10 Years On, Chinese Biopharma Firms Making Inroads In US Clinical Trials

Led by BeiGene, 20 firms have placed their bets on Phase III clinical studies for innovative drugs in the US and some are planning similar new moves despite an ongoing downturn in industry funding, this infographic analysis shows.